BENRALIZUMAB
Benralizumab is a humanized monoclonal antibody targeting the interleukin-5 receptor (IL-5R) on eosinophils, leading to their depletion. It is used as an add-on maintenance treatment for severe eosinophilic asthma in patients aged 12 years and older.-Severe eosinophilic asthma -Chronic respiratory conditions associated with eosinophilia
-Initial dose: 30 mg subcutaneously every 4 weeks for the first 3 doses. -Maintenance: 30 mg subcutaneously every 8 weeks thereafter.
-Hypersensitivity to Benralizumab or its excipients -Acute asthma exacerbations or status asthmaticus
-Not indicated for acute relief of asthma symptoms or exacerbations. -Monitor patients for hypersensitivity reactions during and after administration. -Use with caution in patients with a history of parasitic infections. -Discontinue use if severe allergic reactions occur.
-Common: Headache, sore throat, and injection site reactions -Rare: Hypersensitivity reactions, including anaphylaxis -Serious: Increased risk of infections, especially in immunocompromised patients
-Minimal interaction with other medications as it is a monoclonal antibody. -Concurrent use with systemic corticosteroids should be tapered cautiously to avoid withdrawal symptoms.
